CVRx has now received improved outpatient and inpatient reimbursements for its implantable heart failure device in the last 12 months. The company's president says these updates will help more patients gain access to the Barostim technology. 

The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one. 

Despite raging inflation and rising staff costs, the conversion factor is the lowest it’s been since 1993, Richard Heller, MD, MBA, wrote for MedPage Today. 

Three years after a pair of former hospital C-suite executives blew the whistle on their own institution, the U.S. Department of Justice has acted on the complaint.

The Scottsdale, Arizona, radiology group believes that UHC's contract proposals "don’t recognize the escalating costs of continuing to provide safe and high-quality medical imaging." 

US-first resulted in an incremental net monetary benefit of about $681 versus using diagnostic mammography first, experts wrote in AJR.  

In the year ending July 23, the publicly traded company saw its stock price leap 86% while market capitalization climbed 97%, up to $4.8 billion. 

No industry has taken cybercrime on the chin more than healthcare over the past 13 years. That trend continues in 2024, as global data breaches cost healthcare $9.77 million between March 2023 and February 2024.